Resource Center
Find the latest content and resources from our team of experts to keep you in the know for all things quality and regulatory in the life science industry.
Sort by topic
Sort by resource type
Nitrosamine impurities continue to be a major focus for regulators—and in 2026, scrutiny is not slowing down.
The U.S. Food and Drug Administration is expanding its use of remote and hybrid inspection models, incorporating ...
mRNA technology, which gained global prominence during the COVID-19 pandemic, has since expanded into broader ...
mRNA technology, which gained global prominence during the COVID-19 pandemic, has since expanded into broader ...
A recent $2.7 billion agreement between Eli Lilly and an artificial intelligence-driven drug discovery company is ...
This whitepaper outlines a structured approach to responding to FDA Warning Letters, with a focus on root cause ...
The U.S. Food and Drug Administration is placing increased scrutiny on change control systems across ...
Technology transfer has always been a critical step in bringing products from development to commercial ...
A Warning Letter is issued when the FDA identifies significant violations that have not been adequately addressed ...
The U.S. Food and Drug Administration has approved the first generic omeprazole oral paste for the treatment and ...
AI systems are being used to support critical decisions, including patient selection in clinical trials, ...
BIOSECURE Act is expected to significantly impact how pharmaceutical and biotechnology companies source materials, ...
No results found.